A comparative pharmacodynamic and pharmacokinetic study of Vildagliptin SR 100 mg tablet in normal healthy adult male subjects
Abstract
Background: Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide ≥90% inhibition of DPP-4 over 24 hours. Considering most type 2 diabetes (T2D) patients are on multiple medications, reducing dosing and pill burden can increase patient convenience. A 100 mg Vildagliptin sustained release (SR) formulation that would inhibit DPP-4 ≥ 80% over 24 hours with a lower dosing frequency was developed. The study was thus conducted to evaluate the pharmacodynamics, pharmacokinetics, and safety profile of once-daily Vildagliptin SR compared to twice-daily Vildagliptin immediate-release (IR) formulation.
Results: Twenty-four healthy adult male subjects were enrolled, and 22 completed the clinical phase of the study. The DPP-4 inhibition over time was comparable between the formulations. At 24 hrs single dose of once-daily Vildagliptin SR 100 mg tablet inhibited DPP4 by 89.58%, whereas twice-daily Vildagliptin IR 50 mg by 91.052%. The pharmacokinetic parameters like peak plasma concentration (Cmax), area under the plasma concentration-time curve from 0 hours to the last measurable concentration (AUC0-t) and AUC-time curve up to infinity (AUC0-inf) were not significantly different in both groups. Besides this, both groups reported no serious adverse effects during the study period.
Conclusion: The above result shows that once-daily Vildagliptin SR 100 mg is bioequivalent to twice-daily Vildagliptin IR 50 mg. Moreover, the ability of Vildagliptin SR 100 mg to provide above 80% DPP-4 inhibition coverage over 24 hrs may help to achieve a clinically meaningful glucose-lowering effect and reduce the pill burden in diabetes patients.
Keywords: Vildagliptin, dipeptidyl peptidase IV inhibitor (DPP-4i), type 2 diabetes (T2D) patients, pharmacokinetic parameters
Keywords:
Vildagliptin, dipeptidyl peptidase IV inhibitor (DPP-4i), type 2 diabetes (T2D) patients, pharmacokinetic parametersDOI
https://doi.org/10.22270/jddt.v12i6.5760References
Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019 Jun 19; 10:389. https://doi.org/10.3389/fendo.2019.00389
Pote A, Ravisankar S, Sangle G, Agarwal S, Yarramshetti V, Kale S, Baig ML, Deshmukh S, Shah R, Debnath K, Chitalkar K. Comparative Clinical Pharmacokinetics and Pharmacodynamics of Investigational Once-Daily Sustained-Release (SR) Vildagliptin 100 mg Tablet Formulation with Conventional 50 mg Twice-Daily Regimen in Healthy Indian Males. IJCSRR, 2021; 4(5):445-456 https://doi.org/10.47191/ijcsrr/V4-i5-19
García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013 Dec; 4(2):175-94. https://doi.org/10.1007/s13300-013-0034-y
Narwate BM. Sustained release dosage form: a concise review. International journal of pharmaceutics and drug analysis. 2017 May 2:153-60.
Nagendrakumar D, Keshavshetti GG, Shardor AG. An overview: Matrix tablets as sustained release. Recent Research in Science and Technology. 2014 Jan 14; 5(4). https://doi.org/10.5530/rjps.2015.3.4
Pote, A., Ravisankar, S., Sangle, G., Agarwal, S., Patil, M., Deshmukh, N., Kale, S., Baig, M., Yarramshetti, V., Debnath, K., Shah, R., Ingole, S., & Jain, R. (2021). Clinical pharmacokinetics and pharmacodynamics of vildagliptin 50 mg sustained release tablet formulation in healthy Indian males after single and multiple-dose. International Journal of Research in Medical Sciences, 9(2), 510-517. https://doi.org/10.18203/2320-6012.ijrms20210433
Hauber AB, Han S, Yang JC, Gantz I, Tunceli K, Gonzalez JM, Brodovicz K, Alexander CM, Davies M, Iglay K, Zhang Q, Radican L. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence. 2013 Sep 18; 7:937-49. https://doi.org/10.2147/PPA.S43465
Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011 Jan; 123(1):15-23. https://doi.org/10.3810/pgm.2011.01.2241
Xie W, Song X, Liu Z. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018 Oct; 109:17-26. https://doi.org/10.1016/j.vph.2018.05.010
Published
Abstract Display: 819 
PDF Downloads: 696 PDF Downloads: 81 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.